Rogers Corp. (ROG)

119.08
NYSE : Electronic Technology
Prev Close 120.02
Day Low/High 118.33 / 120.41
52 Wk Low/High 104.25 / 184.00
Avg Volume 163.80K
Exchange NYSE
Shares Outstanding 18.37M
Market Cap 2.15B
EPS 4.40
P/E Ratio 28.11
Div & Yield N.A. (N.A)

Latest News

FDA Approves Additional Claim For Roche Cobas Zika Test

- New claim allows for streamlined screening of pooled blood or plasma donations

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

- Image quality and ease of use set new standard for digital pathology, with the goal of empowering faster, better care for patients

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial...

Rogers Corporation Announces Chief Financial Officer Transition

Rogers Corporation Announces Chief Financial Officer Transition

Rogers Corporation (NYSE:ROG) today announced that Janice E.

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Clinicians to benefit from integrated workflow and faster access to abnormal results

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

-- HITRUST CSF® certification granted for NAVIFY™ Tumor Board solution

Rogers Corporation Reports Fourth Quarter 2017 And Full Year Results

Rogers Corporation Reports Fourth Quarter 2017 And Full Year Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2017 full year and fourth quarter.

Rogers Schedules Q4 & Full Year 2017 Earnings Call For Feb 27

Rogers Schedules Q4 & Full Year 2017 Earnings Call For Feb 27

Rogers Corporation (NYSE:ROG) plans to announce fourth quarter and full year 2017 results on February 27 after market close, which will be followed by a conference call at 5pm ET.

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

- Provides a rapid workflow to aid in the diagnosis of patients with suspected thrombophilia

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer

Rogers To Participate In Needham Growth Conference

Rogers To Participate In Needham Growth Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, and Senior Vice President and CFO, Janice Stipp, will be presenting at the Needham Growth Conference in New York City on Wednesday...

TheStreet Quant Rating: B (Buy)